Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.19.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2018
STOCKHOLDERS' EQUITY (DEFICIT):  
Schedule of share-based compensation, stock options, activity
   

 

Shares Underlying Options  

   

 

Weighted Average Exercise Price  

    Weighted average Remaining Contractual Life (years)      

 

Aggregate Intrinsic Value  

 
Outstanding at December 31, 2017     -     -       -       -  
Acquired in Reverse Merger     133,711       36.42       4.13       -  
Granted     68,347       12.24       9.51       -  
Forfeited     (45,178 )     11.64       -       -  
Outstanding at September 30, 2018     156,880     33.00       4.91       -  
Schedule of share-based compensation
    Three Months ended September 30,       Nine Months ended September 30,    
      2018       2017       2018       2017  
Research and development     2,127       -       8,837       -  
General and administrative     785,609       288,308       1,979,551       709,000  
Total   787,736     288,308     1,988,388     709,000  
Schedule of share-based payment award, stock options, valuation assumptions

 

Fair value of common stock   $10.92 - $13.26
Expected volatility   118.10% - 143.50%
Dividend yield   $0
Risk-free interest   2.85% - 3.00%
Expected life (years)   5.125 - 5.33

Schedule of common stock warrant activity
   

 Number of 

Warrants  

    Weighted Average Exercise Price    
Outstanding, December 31, 2017     146,358     59.04  
Acquired, H-1 warrants     50,744       29.04  
Acquired, H-3 warrants     14,001       33.12  
Granted, H-4 warrants     447,383       3.60  
Granted, I warrants     73,178       13.80  
Granted, J warrants     260,116       6.00  
Exercised, H-4 warrants     (260,116 )     3.60  
Retired, Merger warrants     (146,357 )     59.04  
Outstanding, September 30, 2018     585,307     12.72